EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neurofilament heavy chain in secondary progressive multiple sclerosis

Floriana De Angelis iD, Francesca Ammoscato iD, Richard A Parker, Domenico Plantone iD, Anisha Doshi iD, Nevin A John iD, Thomas Williams, Jonathan Stutters, Dave MacManus iD, Klaus Schmierer iD, Frederik Barkhof iD, Christopher J Weir und 3 weitere

Multiple Sclerosis Journal · 2025-03 · 31 (3) · 303-313

DOI: 10.1177/13524585241311212 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Multiple Sclerosis Journal, online erschienen am 22.01.2025. Verfasst von Floriana De Angelis und 14 weiteren Autor:innen. Beteiligte Einrichtung: Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London Queen Square Institute of Neurology, Faculty of Br…. Hauptthemen laut MEDLINE: Neurofilament Proteins, Multiple Sclerosis, Chronic Progressive. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MS-SMART was funded by Efficacy and Mechanism Evaluation Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biomarkers are needed to track progression in MS trials. Neurofilament heavy chain (NfH) has been underutilized due to assay limitations.

Objective

To investigate the added value of cerebrospinal fluid (CSF) NfH in secondary progressive multiple sclerosis (SPMS) using contemporary immunoassays.

Methods

This exploratory study was part of the MS-SMART trial. Clinical assessments (including expanded disability status scale, upper and lower limb function, visual acuity and symbol digit modalities test (SDMT)), CSF and serum sampling were acquired at baseline ( n = 54), 48 and 96 weeks. Brain magnetic resonance imagings (MRIs) were obtained at baseline and 96 weeks. The NfL and NfH were measured using single-molecule array assay.

Results

Baseline CSF NfH and NfL correlated with information processing speed at 96 weeks, with CSF NfH showing stronger correlations ( r = −0.49 for SDMT) than CSF NfL ( r = −0.37 for SDMT). Baseline CSF NfL predicted poorer hand dexterity at baseline, 48 and 96 weeks. CSF NfH was the only predictor of cortical grey matter at baseline, while baseline CSF NfL was the only predictor of brain atrophy at 96 weeks. Serum neurofilaments showed limited associations.

Conclusion

CSF neurofilaments are better outcomes than serum neurofilaments in small SPMS studies. CSF NfH and NfL variably predict worsening hand function, information processing speed and brain volume loss, possibly reflecting complementary aspects of neurodegeneration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofilament ProteinsMultiple Sclerosis, Chronic ProgressiveHumansMaleFemaleMiddle AgedAdultBiomarkersDisease ProgressionMagnetic Resonance ImagingBrain

Stichwörter der Autor:innen

Neurofilamentsbiomarkersprogressive multiple sclerosis

Substanzen

Neurofilament ProteinsBiomarkersneurofilament protein Lneurofilament protein H

Autor:innen und Institutionen

  • Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • National Institute for Health and Care Research, University College London Hospitals Biomedical Research Centre, London, UK.
  • Blizard Institute, Barts and The London, London, UK.
  • Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK.
  • Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
  • Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, VIC, Australia.

ORCID-Profile: Floriana De Angelis, Francesca Ammoscato, Domenico Plantone, Anisha Doshi, Nevin A John, Dave MacManus, Klaus Schmierer, Frederik Barkhof

Förderung

  • MS-SMART was funded by Efficacy and Mechanism Evaluation Programme

Zitieren

APA

De Angelis, F., Ammoscato, F., Parker, R. A., Plantone, D., Doshi, A., John, N. A., Williams, T., Stutters, J., MacManus, D., Schmierer, K., Barkhof, F., Weir, C. J., Giovannoni, G., Chataway, J., & Gnanapavan, S. (2025). Neurofilament heavy chain in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 31(3), 303-313. https://doi.org/10.1177/13524585241311212

Vancouver

De Angelis F, Ammoscato F, Parker RA, Plantone D, Doshi A, John NA, et al. Neurofilament heavy chain in secondary progressive multiple sclerosis. Multiple Sclerosis Journal. 2025;31(3):303-313. doi:10.1177/13524585241311212

BibTeX
@article{DeAngelis2025,
  author = {De Angelis, Floriana and Ammoscato, Francesca and Parker, Richard A and Plantone, Domenico and Doshi, Anisha and John, Nevin A and Williams, Thomas and Stutters, Jonathan and MacManus, Dave and Schmierer, Klaus and Barkhof, Frederik and Weir, Christopher J and Giovannoni, Gavin and Chataway, Jeremy and Gnanapavan, Sharmilee},
  title = {Neurofilament heavy chain in secondary progressive multiple sclerosis},
  journal = {Multiple Sclerosis Journal},
  year = {2025},
  volume = {31},
  number = {3},
  pages = {303--313},
  doi = {10.1177/13524585241311212}
}
Kostenlos starten →